Shares of Ionis Pharmaceuticals Inc. were down 19.6% in premarket trading on Tuesday, the day after the company said Roche Holding AG decided to discontinue a late-stage clinical trial for a Huntington’s disease treatment candidate. Roche licensed the investigational therapy, tominersen, from Ionis in December 2017. However, an independent data monitoring committee first made the recommendation to discontinue the study. “The program isn’t necessarily dead, but it’s unlikely to drive much value for the stock near term,” Bernstein’s Vincent Chen wrote in a note to investors on Tuesday. “This discontinuation doesn’t mean that the program is dead. It depends on why it failed.” Ionis’ stock is up 33.7% over the past 12 months, while the broader S&P 500 has gained 70.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.